Cargando…

Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies

BACKGROUND: Myositis-specific autoantibodies (MSAs) are clinically used to diagnose and define idiopathic inflammatory myopathy (IIM) subsets. However, the underlying pathogenic mechanisms of patients with different MSAs remain unclear. METHODS: A total of 158 Chinese patients with IIM and 167 gende...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengdi, Zhang, Yusheng, Zhang, Wenzhe, Sun, Jinlei, Liu, Rui, Pan, Zhou, Zhang, Panpan, Liu, Shengyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203462/
https://www.ncbi.nlm.nih.gov/pubmed/37228600
http://dx.doi.org/10.3389/fimmu.2023.1169057
_version_ 1785045636789305344
author Li, Mengdi
Zhang, Yusheng
Zhang, Wenzhe
Sun, Jinlei
Liu, Rui
Pan, Zhou
Zhang, Panpan
Liu, Shengyun
author_facet Li, Mengdi
Zhang, Yusheng
Zhang, Wenzhe
Sun, Jinlei
Liu, Rui
Pan, Zhou
Zhang, Panpan
Liu, Shengyun
author_sort Li, Mengdi
collection PubMed
description BACKGROUND: Myositis-specific autoantibodies (MSAs) are clinically used to diagnose and define idiopathic inflammatory myopathy (IIM) subsets. However, the underlying pathogenic mechanisms of patients with different MSAs remain unclear. METHODS: A total of 158 Chinese patients with IIM and 167 gender- and age-matched healthy controls (HCs) were enrolled. Transcriptome sequencing (RNA-Seq) was performed with peripheral blood mononuclear cells (PBMCs), followed by the identification of differentially expressed genes (DEGs) and analysis of gene set enrichment analysis, immune cell infiltration, and WGCNA. Monocyte subsets and related cytokines/chemokines were quantified. The expressions of interferon (IFN)-related genes were validated using qRT-PCR and Western blot in both PBMCs and monocytes. We also performed correlation analysis and ROC analysis to explore the potential clinical significance of the IFN-related genes. RESULTS: There were 1,364 genes altered in patients with IIM, including 952 upregulated and 412 downregulated genes. The type I interferon (IFN-I) pathway was remarkably activated in patients with IIM. Compared with patients with other MSAs, IFN-I signatures were significantly activated in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies. In total, 1,288 hub genes associated with IIM onset were identified using WGCNA, including 29 key DEGs associated with IFN signaling. The patients had more CD14brightCD16- classical, CD14brightCD16+ intermediate, and fewer CD14dimCD16+ non-classical monocyte subsets. Plasma cytokines like IL-6 and TNF and chemokines including CCL3 and MCPs increased. The validation of IFN-I-related gene expressions was consistent with the findings from RNA-Seq. The IFN-related genes were correlated with laboratory parameters and helpful for IIM diagnosis. CONCLUSION: Gene expressions were remarkably altered in the PBMCs of IIM patients. Anti-MDA5+ IIM patients had a more pronounced activated IFN signature than others. Monocytes exhibited a proinflammatory feature and contributed to the IFN signature of IIM patients.
format Online
Article
Text
id pubmed-10203462
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-102034622023-05-24 Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies Li, Mengdi Zhang, Yusheng Zhang, Wenzhe Sun, Jinlei Liu, Rui Pan, Zhou Zhang, Panpan Liu, Shengyun Front Immunol Immunology BACKGROUND: Myositis-specific autoantibodies (MSAs) are clinically used to diagnose and define idiopathic inflammatory myopathy (IIM) subsets. However, the underlying pathogenic mechanisms of patients with different MSAs remain unclear. METHODS: A total of 158 Chinese patients with IIM and 167 gender- and age-matched healthy controls (HCs) were enrolled. Transcriptome sequencing (RNA-Seq) was performed with peripheral blood mononuclear cells (PBMCs), followed by the identification of differentially expressed genes (DEGs) and analysis of gene set enrichment analysis, immune cell infiltration, and WGCNA. Monocyte subsets and related cytokines/chemokines were quantified. The expressions of interferon (IFN)-related genes were validated using qRT-PCR and Western blot in both PBMCs and monocytes. We also performed correlation analysis and ROC analysis to explore the potential clinical significance of the IFN-related genes. RESULTS: There were 1,364 genes altered in patients with IIM, including 952 upregulated and 412 downregulated genes. The type I interferon (IFN-I) pathway was remarkably activated in patients with IIM. Compared with patients with other MSAs, IFN-I signatures were significantly activated in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibodies. In total, 1,288 hub genes associated with IIM onset were identified using WGCNA, including 29 key DEGs associated with IFN signaling. The patients had more CD14brightCD16- classical, CD14brightCD16+ intermediate, and fewer CD14dimCD16+ non-classical monocyte subsets. Plasma cytokines like IL-6 and TNF and chemokines including CCL3 and MCPs increased. The validation of IFN-I-related gene expressions was consistent with the findings from RNA-Seq. The IFN-related genes were correlated with laboratory parameters and helpful for IIM diagnosis. CONCLUSION: Gene expressions were remarkably altered in the PBMCs of IIM patients. Anti-MDA5+ IIM patients had a more pronounced activated IFN signature than others. Monocytes exhibited a proinflammatory feature and contributed to the IFN signature of IIM patients. Frontiers Media S.A. 2023-05-09 /pmc/articles/PMC10203462/ /pubmed/37228600 http://dx.doi.org/10.3389/fimmu.2023.1169057 Text en Copyright © 2023 Li, Zhang, Zhang, Sun, Liu, Pan, Zhang and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Li, Mengdi
Zhang, Yusheng
Zhang, Wenzhe
Sun, Jinlei
Liu, Rui
Pan, Zhou
Zhang, Panpan
Liu, Shengyun
Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title_full Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title_fullStr Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title_full_unstemmed Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title_short Type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
title_sort type 1 interferon signature in peripheral blood mononuclear cells and monocytes of idiopathic inflammatory myopathy patients with different myositis-specific autoantibodies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203462/
https://www.ncbi.nlm.nih.gov/pubmed/37228600
http://dx.doi.org/10.3389/fimmu.2023.1169057
work_keys_str_mv AT limengdi type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT zhangyusheng type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT zhangwenzhe type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT sunjinlei type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT liurui type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT panzhou type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT zhangpanpan type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies
AT liushengyun type1interferonsignatureinperipheralbloodmononuclearcellsandmonocytesofidiopathicinflammatorymyopathypatientswithdifferentmyositisspecificautoantibodies